Imaging Center COE

RADAR II Group Recommendations - The Role of Therapeutic Layering

Details
David Crawford, MD discusses with Thomas Keane, MD, the paper, RADAR II: The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer, which was designed to offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostat...

Imaging Controversies in Prostate Cancer- Interview with Phillip Koo

Details
Imaging Controversies for Assessing Localized and Advanced PCa, an Interview with Charles Ryan and Phillip Koo Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of interview: 6 min) Dr. Phillip Koo talks with Charles Ryan, MD about imaging controversies when it comes to local and metastatic disease. He overviews his LUGPA 2017 presentation on local disease in a practical and c...

18F-DCFBC PET/CT with Multiparametric MRI and Histopathology - Liza Lindenberg

Details
(Length of lecture ~ 8 minutes) Prostate-specific membrane antigen (PSMA) is over-expressed in prostate cancer, so it is a good target to use for diagnoses and treatment. 18F-DCFBC binds to the external domain of PSMA, so when it is used as a PET tracer it can be very helpful in improving imaging of localized and metastatic prostate cancer. The goal of this research is to asses the ability of 18F-...

The Additional Value of PET for MRI Guided Transrectal Prostate Biopsies - Morand Piert

Details
(Length of lecture - 12 minutes) In this presentation Dr. Piert discusses the random aspects of standard extended-sextant ultrasound-guided biopsy and the study that was designed to assess targeted vs standard biopsy and the 2 approaches combined for the diagnosis of intermediate- to high-risk prostate cancer. These trial results are published in JAMA, "Comparison of MR/ultrasound fusion-guided bi...

Ga-68 PSMA Lyophilized Ready to Use Kit for Diagnosis of Prostate Cancer by PET/CT - Stephan Maus

Details
(Length of lecture ~ 13 minutes) Stephan Maus discusses Ga-68 labeled prostate-specific membrane antigen (PSMA) whole body PET/CT scan cold kit for the detection of prostate cancer lesions. Specifically, cold kit procedures have been under intense investigation due to their shortened synthesis times, reduced error rates and eliminating expensive hardware, making it a reliable alternative. This pre...

What the Referring Clinician Needs to Know from Molecular Imaging in Prostate Cancer - Felix Feng

Details
(Length of lecture ~ 16 minutes) Dr. Feng provides a brief overview of prostate cancer management and how molecular imaging approaches can help guide the clinical management of prostate cancer, noting that imaging physicians need to educate their clinical colleagues about capabilities and limitations of these imaging studies. Additional content on molecular imaging ASCO 2017: How Advances in Molec...

18F-Fluciclovine: A New Option for Biochemical Recurrence in Prostate Cancer - Trond V. Bogsrud

Details
(Length of lecture ~ 15 minutes) Trond V. Bogsrud, MD presented "18F-Fluciclovine: A New Option for Biochemical Recurrence in Prostate Cancer” at the SNMMI 2016, detailing the uptake of fluciclovine (18F) as a PET imaging radiotracer in comparison to other PET tracers in patients with biochemically recurrent prostate cancer. Additional content on 18F - Fluciclovine Stepping Into the Light: "Radiol...

Using Fluciclovine in the Recurrent Prostate Cancer Patient- David Schuster

Details
Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. (Length of lecture 57 minutes) In this lecture, David Schuster describes the mechanisms of uptake of the PET radiotracer fluciclovine and identifies normal biodistribution of fluciclovine. In addition, Dr. Schuster discusses the FDA approval and clinical indication of fluciclovine and the clinical inter...

Biochemically Recurrent Prostate Cancer: Superior Agents to Conventional Imaging - Andrei Iagaru

Details
Dr. Andrei Iagaru states that the significantly changing landscape of prostate cancer diagnoses is due to new and improved imaging agents and access to resources that were once available only outside of the United State. In this particular study, 68 GA-RM2, formerly known as 68 Ga-Bombesin or BAY86-7548 PET/MRI was compared to conventional imaging for patients with biochemically recurring prostate...

PSMA PET/CT- Struggling with Increased Sensitivity

Details
Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. (Length of video ~ 23 minutes) Michael Hofman discusses PSMA as the new “gold standard” and how it is significantly superior to existing imaging modalities through case studies from the Peter MacCallum Cancer Centre and a review of abstracts. Related content: Systemic Radioligand Therapy with (177)Lu La...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe